On The Pen GLP-1 News
von Dave Knapp GLP-1 Industry Insider
Retatrutide Phase 3 Results: What You Need to Know
Über diesen Podcast
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 0.5% of all podcasts globally, and On The Pen is a top Substack best-seller.
Folgen
Die neuesten 20 von 215 Folgen
- Retatrutide Phase 3 Results: What You Need to Know · 32 Min.Retatrutide’s New Phase 3 Data, CagriSema in Menopause, and the Growing GLP‑1 Access CrisisHost Dave Knapp recaps major obesity-drug updates, focusing on Eli Lilly’s triple…
- GLP-1 Recall Update: Why You Need to Check Your Vials · 27 Min.Specific lots of compounded tirzepatide have been recalled over sterility concerns, another pharmacy recently recalled compounded semaglutide after particulate matter was…
- Eli Lilly vs. The Grey Market: The Future of Peptide Medicine · 25 Min.Eli Lilly’s fight over retatrutide may be about much more than one obesity drug.I’ve been covering retatrutide since early 2023, and since late 2024 I’ve been closely following…
- Ozempic & Zepbound Are Changing America in Ways Nobody Expected · 25 Min.Zepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself. Restaurants are rethinking what they serve. Grocery baskets are changing…
- They TRIPLED Wegovy Dose, Does it Beat Zepbound? · 31 Min.This week on On The Pen, The Weekly Dose, we break down one of the biggest weeks in obesity medicine coming out of EASD 2026.Eli Lilly says Zepbound may still outperform Wegovy…
- Retatrutide in Court, Compound GLP-1 Under Fire · 30 Min.This week on On The Pen, The Weekly Dose Podcast, retatrutide heads into a major federal court fight as the Department of Justice gives FDA fresh legal ammunition just days…
- 17% Weight Loss in 16 Weeks… Is This Better Than Retatrutide? · 30 Min.Lilly just gave us a glimpse of what could come after today’s GLP-1s, and it may not be about simply pushing patients to stronger drugs and higher doses. This week on On The…
- GLP-1 for 6 Year Olds? Here’s What the Trial Actually Found · 26 Min.Is obesity still a disease worthy of treatment when the patient is six years old? This week, Novo Nordisk released Phase 3 STEP Young data in children ages 6 to 11 with obesity…
- We’re Solving Obesity. Now Who Pays for It? · 25 Min.This week on On The Pen, the GLP-1 story is moving in two very different directions. The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide…
- GLP-1 Coverage Is COLLAPSING in 2027 · 35 Min.GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health. In this episode of the On The Pen…
- $50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold” · 45 Min.Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity…
- 200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study · 31 Min.Https://www.otplinks.com Based on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are…
- Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In. · 19 Min.Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s…
- Retatrutide Biologic Battle: The Story Gets Bigger · 21 Min.https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks…
- GLP-1 Showdown: Inside The High Stakes War over Patients · 27 Min.Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being…
- Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know · 32 Min.What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity…
- Compound GLP-1 Poll STUNS THE INTERNET! · 16 Min.What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to do with…
- How To Get $50 GLP-1 · 45 Min.Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching…
- What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs · 1 Std. 15 Min.ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down…








